ArticleCommunications medicine2024

Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial.

Norah G Verbout et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.